[go: up one dir, main page]

CL2019002800A1 - Tratamiento conjunto antineoplásico - Google Patents

Tratamiento conjunto antineoplásico

Info

Publication number
CL2019002800A1
CL2019002800A1 CL2019002800A CL2019002800A CL2019002800A1 CL 2019002800 A1 CL2019002800 A1 CL 2019002800A1 CL 2019002800 A CL2019002800 A CL 2019002800A CL 2019002800 A CL2019002800 A CL 2019002800A CL 2019002800 A1 CL2019002800 A1 CL 2019002800A1
Authority
CL
Chile
Prior art keywords
joint
antineoplastic treatment
antineoplastic
antagonist
treatment
Prior art date
Application number
CL2019002800A
Other languages
English (en)
Inventor
Markus Reschke
Dorothea Rudolph
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019002800A1 publication Critical patent/CL2019002800A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCIÓN DESCRIBE TRATAMIENTOS ANTINEOPLÁSICOS QUE COMPRENDEN EL USO DE UN INHIBIDOR DE MDM2 EN COMBINACIÓN CON UN ANTAGONISTA DE PD-1 Y UN ANTAGONISTA DE LAG-3, CADA UNO COMO SE DESCRIBE EN LA PRESENTE.
CL2019002800A 2017-04-05 2019-10-01 Tratamiento conjunto antineoplásico CL2019002800A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17165111 2017-04-05
EP17197930 2017-10-24

Publications (1)

Publication Number Publication Date
CL2019002800A1 true CL2019002800A1 (es) 2020-03-06

Family

ID=61899297

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002800A CL2019002800A1 (es) 2017-04-05 2019-10-01 Tratamiento conjunto antineoplásico
CL2023002946A CL2023002946A1 (es) 2017-04-05 2023-10-02 Tratamiento conjunto antineoplásico

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023002946A CL2023002946A1 (es) 2017-04-05 2023-10-02 Tratamiento conjunto antineoplásico

Country Status (12)

Country Link
US (2) US20200101079A1 (es)
EP (2) EP3606556A1 (es)
JP (2) JP2020516604A (es)
KR (2) KR20240090927A (es)
CN (2) CN110505884B (es)
AU (1) AU2018248586A1 (es)
BR (1) BR112019021032A2 (es)
CA (1) CA3057558A1 (es)
CL (2) CL2019002800A1 (es)
MX (1) MX2019011945A (es)
PH (1) PH12019502291A1 (es)
WO (1) WO2018185135A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
RS62258B1 (sr) 2015-10-02 2021-09-30 Hoffmann La Roche Bispecifična antitela specifična za pd1 i tim3
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
JP7426825B2 (ja) 2017-04-03 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート
US11285207B2 (en) 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
MX2020009614A (es) * 2018-03-20 2020-10-07 Novartis Ag Combinaciones farmaceuticas.
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2019316865A1 (en) * 2018-08-08 2020-12-17 Ascentage Pharma (Suzhou) Co., Ltd. Combination of immunotherapies with MDM2 inhibitors
EP4603098A3 (en) * 2018-11-01 2025-09-03 Alpha Tau Medical Ltd. Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
AR116904A1 (es) * 2018-12-11 2021-06-23 Kartos Therapeutics Inc Métodos y composiciones para el tratamiento de un trastorno oftálmico
CA3226022A1 (en) 2021-08-09 2023-02-16 Boehringer Ingelheim International Gmbh Oral composition comprising a mdm2-antagonist for cancer therapy
CN115089585A (zh) * 2022-08-05 2022-09-23 中国科学院大学宁波华美医院 Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用
TW202440585A (zh) * 2022-12-22 2024-10-16 德商百靈佳殷格翰國際股份有限公司 MDM2-p53抑制劑之晶型及醫藥組合物
WO2024238404A2 (en) * 2023-05-12 2024-11-21 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
BRPI0713119A2 (pt) 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
AR065860A1 (es) 2007-03-29 2009-07-08 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
JP5844159B2 (ja) * 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
KR20160055269A (ko) 2013-09-20 2016-05-17 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3129380B1 (en) 2014-04-11 2018-11-28 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
HRP20191414T1 (hr) 2014-08-21 2019-11-01 Boehringer Ingelheim Int Novi spojevi i derivati spiro[3h-indol-3,2'-pirolidin]-2(1h)-ona kao mdm1-p53-inhibitori
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20170340733A1 (en) * 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) * 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
HUE054985T2 (hu) * 2015-10-09 2021-11-29 Boehringer Ingelheim Int Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok
KR20220103806A (ko) * 2016-05-18 2022-07-22 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 항-pd1 및 항-lag3 항체
WO2019063802A1 (en) * 2017-09-29 2019-04-04 Boehringer Ingelheim International Gmbh ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1

Also Published As

Publication number Publication date
JP2024029009A (ja) 2024-03-05
EP3606556A1 (en) 2020-02-12
BR112019021032A2 (pt) 2020-05-05
CN114949228A (zh) 2022-08-30
EP4368200A3 (en) 2024-07-17
KR20190132687A (ko) 2019-11-28
WO2018185135A1 (en) 2018-10-11
AU2018248586A1 (en) 2019-09-05
US20200101079A1 (en) 2020-04-02
MX2019011945A (es) 2019-11-28
PH12019502291A1 (en) 2020-07-06
CL2023002946A1 (es) 2024-04-19
EP4368200A2 (en) 2024-05-15
US20230025452A1 (en) 2023-01-26
CA3057558A1 (en) 2018-10-11
JP2020516604A (ja) 2020-06-11
CN110505884B (zh) 2022-08-12
CN110505884A (zh) 2019-11-26
KR20240090927A (ko) 2024-06-21

Similar Documents

Publication Publication Date Title
CL2023002946A1 (es) Tratamiento conjunto antineoplásico
CL2021003353A1 (es) Tratamiento conjunto antineoplásico.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
CL2019002742A1 (es) Tratamiento conjunto antineoplásico.
CO2020004921A2 (es) Derivado de pirrolobenzodiazepina inmunoconjugado
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2020000301A1 (es) Nuevos derivados de quinolina.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
MX2016014581A (es) Composiciones de compuestos que modulan nmdar.
MX2019006950A (es) Metodos para tratar la sinaptopatia coclear.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
EA202191556A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
MX388780B (es) Uso de un compuesto de lignina para fertilizantes de urea con dureza mejorada.
BR112017011433A2 (pt) roda abrasiva não tecida com uma camada de barreira à umidade
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
CL2018002638A1 (es) Ambrisentan para uso en el tratamiento de insuficiencia renal aguda
BR112018072255A2 (pt) azasteroides para tratamento de tuberculose